Mereo BioPharma (MREO)

• Market cap: $48.4M
• 1 day: -5.77%
• 5 days: -4.59%
• 1 month: -4.14%
• 3 months: 8.9%
• 6 months: -19.07%
• Year to date: -40.54%
• 1 year: -81.38%
• 5 years: -88.68%
• 10 years: -95.33%
• Sector: Healthcare
• Industry: Biotechnology

About: Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Employees: 39